Luca Nicosia, Radiation Oncologist at the Department of Advanced Radiation Oncology at IRCCS, shared a post on X:
“PLATO ATC4 phase II trial
- Reduced dose for T1 T2 <4 cm achieved similar results to standard dose.
- Reduced treatment interruption
- optimal QoL.”
More posts featuring ESTRO.
